Price$74.41+2.94 (+4.12%)
01:30 PM07:15 PM
News · 26 weeks37+86%
2025-12-142026-06-07
Mix2390d
- Insider8(35%)
- Other7(30%)
- SEC Filings4(17%)
- Earnings2(9%)
- Analyst2(9%)
Latest news
25 items- SECHaemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - HAEMONETICS CORP (0000313143) (Filer)
- PRHaemonetics Updates Financial Reporting SegmentsBOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced an update to its reportable segment structure to better align external financial reporting with how the Company manages its business and allocates resources. Under the new structure, Haemonetics will transition from three reportable segments to two. The previously reported Plasma and Blood Center segments will be combined into a single reportable segment, Apheresis, while the Hospital segment will be renamed MedSurg. The updated segment names more accurately reflect the underlying business
- PRHaemonetics to Present at Goldman Sachs 47th Annual Global Healthcare ConferenceBOSTON, June 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. ET.The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link:https://event.webcasts.com/starthere.jsp?ei=1766065&tp_key=0b16b4b62d&tp_special=8A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.ABOUT HAEMONETICSHaemonetics is a global medical technology co
- SECSEC Form SD filed by Haemonetics CorporationSD - HAEMONETICS CORP (0000313143) (Filer)
- ANALYSTHaemonetics upgraded by BofA Securities with a new price targetBofA Securities upgraded Haemonetics from Neutral to Buy and set a new price target of $80.00
- SECSEC Form 10-K filed by Haemonetics Corporation10-K - HAEMONETICS CORP (0000313143) (Filer)
- INSIDEREVP and General Counsel Basil Michelle L covered exercise/tax liability with 2,913 shares and was granted 28,424 shares, increasing direct ownership by 59% to 68,829 units (SEC Form 4) (tax withholding)4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDEREVP, Chief Operating Officer Chan Frank was granted 27,535 shares and covered exercise/tax liability with 546 shares, increasing direct ownership by 454% to 32,936 units (SEC Form 4) (tax withholding)4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDEREVP, Chief Financial Officer Darecca James covered exercise/tax liability with 2,505 shares and was granted 29,312 shares, increasing direct ownership by 97% to 54,444 units (SEC Form 4) (for withholding tax)4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDERVP, Chief Accounting Officer Maunsell Farris Maryanne covered exercise/tax liability with 197 shares and was granted 2,220 shares, increasing direct ownership by 45% to 6,501 units (SEC Form 4) to cover taxes4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDEREVP, Chief Commercial Officer Galvin Roy covered exercise/tax liability with 879 shares and was granted 27,535 shares, increasing direct ownership by 202% to 39,882 units (SEC Form 4) to satisfy withholding tax4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDERSVP, Human Resources Miller Laurie A. covered exercise/tax liability with 948 shares and was granted 13,323 shares, increasing direct ownership by 43% to 41,300 units (SEC Form 4) to cover withholding tax4 - HAEMONETICS CORP (0000313143) (Issuer)
- INSIDERPresident & CEO Simon, Christopher covered exercise/tax liability with 9,681 shares and was granted 78,344 shares, increasing direct ownership by 18% to 444,704 units (SEC Form 4) (withholding obligation)4 - HAEMONETICS CORP (0000313143) (Issuer)
- ANALYSTBarrington Research reiterated coverage on Haemonetics with a new price targetBarrington Research reiterated coverage of Haemonetics with a rating of Outperform and set a new price target of $89.00 from $94.00 previously
- PRHaemonetics Corporation Announces Fourth Quarter Fiscal 2026 Financial Results Available on Investor Relations WebsiteFinancial release and supplemental presentation accessible onlineBOSTON, May 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter fiscal year 2026, which ended March 28, 2026, are available on the Company's Investor Relations website at www.haemonetics.com.The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 7, 2026.Conference Call and Webcast Information:Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the event
- SECHaemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - HAEMONETICS CORP (0000313143) (Filer)
- INSIDEREVP, Chief Financial Officer Darecca James covered exercise/tax liability with 655 shares, decreasing direct ownership by 2% to 27,637 units (SEC Form 4) (withholding tax)4 - HAEMONETICS CORP (0000313143) (Issuer)
- PRHaemonetics to Present at Bank of America 2026 Healthcare ConferenceBOSTON, May 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Bank of America 2026 Healthcare Conference on Tuesday, May 12, 2026 at 8:00 a.m. PT.The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://bofa.veracast.com/webcasts/bofa/healthcare2026/75d0U1.cfm.A replay of the recorded webcast will become accessible within 24 hours after the event and will be available for one year on Haemonetics' Investor Relations website.ABOUT HAEMONETICSHaemonetics is a global medical technology company dedicated to
- SECHaemonetics Corporation filed SEC Form 8-K: Leadership Update8-K - HAEMONETICS CORP (0000313143) (Filer)
- PRNew Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure ProceduresBOSTON, April 24, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the publication of a new study comparing its VASCADE MVP® XL vascular closure system with the VASCADE MVP® venous vascular closure system in the context of large‐bore venous access closure procedures. This study, "VASCADE MVP-XL Versus VASCADE MVP for Large-Bore Venous Access-Site Closure in Electrophysiology Procedures: A Single-Center Experience on Efficacy and Complications," was published earlier this week in the Journal of Cardiovascular Electrophysiology.The retrospective, non‐rand
- PRHaemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026BOSTON, April 1, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May 7, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 7, 2026. The call can be accessed via teleconference at: Q4 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While n
- PRHaemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure SystemVASCADE MVP XL now approved for larger sheaths used in market-leading PFA and LAAC technologiesBOSTON, March 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval to expand the labeling for the VASCADE MVP® XL venous vascular closure system to include procedures using 10-14F inner diameter (ID) and up to 17F outer diameter (OD) procedural sheaths. With this label expansion, the VASCADE MVP XL system is approved for larger sheaths used in market-leading technologies for pulsed field ablation (PFA) and left
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Haemonetics CorporationSCHEDULE 13G/A - HAEMONETICS CORP (0000313143) (Subject)
- SECHaemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure8-K - HAEMONETICS CORP (0000313143) (Filer)
- PRHaemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS TechnologyBOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS® Plasma Collection System with Persona® PLUS technology. Persona PLUS represents the next generation of Haemonetics' proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation. The 510(k) clearance was supported by clinical
HAE FAQ
7 questionsWhat does Haemonetics Corporation do?
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood...Where does HAE stock trade?
Haemonetics Corporation (HAE) is listed on NYSE.What sector and industry is HAE in?
Haemonetics Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did Haemonetics Corporation go public?
Haemonetics Corporation (HAE) completed its IPO in 1991.What are analysts saying about HAE?
Haemonetics Corporation has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy on 2026-05-22.What companies are similar to HAE?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare HAE side-by-side with any of them on Quantisnow.How can I track HAE on Quantisnow?
Quantisnow aggregates Haemonetics Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HAE to receive live email and push alerts on every new disclosure.